Marksans Pharma’s arm gets marketing authorization from UK MHRA

05 Nov 2025 Evaluate

Marksans Pharma’s wholly owned subsidiary -- Relonchem in UK has received marketing authorization for its product Exemestane 25mg film-coated tablets from UK Medicines & Healthcare products Regulatory Agency (UK MHRA). 

In August 2025, Relonchem had received marketing authorization for Metformin Hydrochloride Relonchem 500 mg, 750 mg and 1000 mg Prolonged Release Tablets.

Marksans Pharma is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets.

Marksans Pharma Share Price

183.95 -3.95 (-2.10%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×